Utilizing a protein domain-focused CRISPR-Cas9 screen, our studies revealed that BRD4, DOT1L, HDAC3 and MOZ could serve as effective co-targets to achieve synergistic efficacy with LSD1i against AML and sAML cells. This evidence concerns the gene DOT1L and acute myeloid leukemia.